Randomized Controlled Study of Plasma Exchange Combined with Molecular Adsorbent Re-Circulating System for the Treatment of Liver Failure Complicated with Hepatic Encephalopathy

Yu-Kun Huang,De-Ming Tan,Yu-Tao Xie,Xue-Gong Fan,Yan Huang,Zheng-Bo Liu,Sha-Ling Li
DOI: https://doi.org/10.5754/hge12203
2012-01-01
Abstract:Background/Aims: To evaluate the use of plasma exchange (PE) combined with the molecular adsorbent re-circulating system (MARS) for the treatment of liver failure complicated with hepatic encephalopathy. Methodology: A prospective randomized controlled study was conducted to compare the therapeutic effect of MARS treatment (MARS group, n=60) with that of PE combined with MARS treatment (PE+MARS group, n=60) in patients with liver failure complicated with hepatic encephalopathy. Results: The serum total bilirubin and blood ammonia levels were significantly decreased compared with pretreatment levels after 3 days of both the MARS treatment (p=0.0001, p < 0.001) and PE+MARS treatment (both p < 0.0001) and the Glasgow coma scale score was significantly increased (both p < 0.0001). The 30-day mortality rate was 10.0% (6/60) in the MARS group and 11.7% (7/60) in the PE + MARS group. The per capita cost of treatment was significantly lower in the PE + MARS group than in the MARS group (p=0.0003). Conclusions: Both MARS and PE + MARS therapy can safely and effectively be used to treat liver failure complicated with hepatic encephalopathy, but PE + MARS therapy reduces serum total bilirubin level more effectively and is more cost-effective.
What problem does this paper attempt to address?